Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance

por Ernst, Tina, Aebi, Stefan, Zander, Andrea, Zander, Thilo
Publicado 2022

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma

por Bohler, Jeanne, Bacher, Ulrike, Banz, Yara, Stadelmann, Raphael, Medinger, Michael, Zander, Thilo, Pabst, Thomas
Publicado 2022

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

por Heini, Alexander D., Beck, Philipp, Bacher, Ulrike, Seipel, Katja, Zander, Thilo, Daskalakis, Michael, Pabst, Thomas
Publicado 2023

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

por Farag, Sarah, Bacher, Ulrike, Jeker, Barbara, Legros, Myriam, Rhyner, Gaelle, Lüthi, Jean-Marc, Schardt, Julian, Zander, Thilo, Daskalakis, Michael, Mansouri, Behrouz, Manz, Chantal, Pabst, Thomas
Publicado 2022

Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial

por Zander, Thilo, Pabst, Thomas, Schär, Sämi, Aebi, Stefan, Mey, Ulrich, Novak, Urban, Lerch, Erika, Rhyner Agocs, Gaëlle, Goede, Jeroen, Maniecka, Zuzanna, Hayoz, Stefanie, Rüfer, Axel, Renner, Christoph, Driessen, Christoph
Publicado 2023

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the Eur...

por Novak, Urban, Fehr, Martin, Schär, Sämi, Dreyling, Martin, Schmidt, Christian, Derenzini, Enrico, Zander, Thilo, Hess, Georg, Mey, Ulrich, Ferrero, Simone, Mach, Nicolas, Boccomini, Carola, Böttcher, Sebastian, Voegeli, Michèle, Cairoli, Anne, Ivanova, Vanesa-Sindi, Menter, Thomas, Dirnhofer, Stefan, Scheibe, Bernhard, Gadient, Sandra, Eckhardt, Katrin, Zucca, Emanuele, Driessen, Christoph, Renner, Christoph
Publicado 2023